Soufflé Therapeutics Secures $135 Million in Series B Funding

Soufflé Therapeutics Secures $135 Million in Series B Funding

Soufflé Therapeutics, a Boston-based company specializing in the development of safer and more durable genetic medicines, has announced the successful close of its Series B funding round, raising $135 million. The company, known for assembling a team of experts in genetic medicine, aims to enhance the safety and effectiveness of its medicinal offerings.

Funding Details

The Series B round, completed on October 13, 2026, did not disclose specific investors or a lead investor. This substantial funding will support Soufflé Therapeutics in its mission to develop innovative genetic therapies.

Use of Funds

While specific plans for the newly acquired funds have not been detailed, companies in this sector typically allocate such investments towards research and development, clinical trials, and possibly expanding their team of experts to further their genetic medicine initiatives.

Location

Soufflé Therapeutics is headquartered in Boston, Massachusetts, United States.

This new influx of capital will likely bolster Soufflé Therapeutics' efforts to bring more robust genetic therapies to market, enhancing their ability to address unmet medical needs through advanced genetic solutions.